NCT02220660View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2009

Conditions
Healthy
Interventions
DRUG

BI 1744 CL

DRUG

BI 54903 XX

DRUG

BI 1744 CL + BI 54903 XX FDC

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY